MapLight Therapeutics (MPLT) Total Current Liabilities (2024 - 2025)
MapLight Therapeutics (MPLT) reported Total Current Liabilities of $16.2 million for Q4 2025, up 1.94% on a YoY basis from $15.9 million in Q4 2024, and down 12.57% sequentially from $18.6 million in Q3 2025.
MapLight Therapeutics (MPLT) Total Current Liabilities (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Total Current Liabilities data on file, last reported at $16.2 million in Q4 2025.
- For the quarter ending Q4 2025, Total Current Liabilities rose 1.94% year-over-year to $16.2 million; the trailing twelve-month figure through Dec 2025 stood at $16.2 million (up 1.94% YoY), and the FY2025 full-year result was $16.2 million, up 1.94% from the prior year.
- Total Current Liabilities eased to $16.2 million in Q4 2025, from $18.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $18.6 million in Q3 2025 to a low of $15.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - | 16.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.23 Mn |
| Sep 30, 2025 | 18.56 Mn |
| Dec 31, 2024 | 15.92 Mn |